% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mai:127048,
      author       = {E. K. Mai and U. Bertsch and J. Dürig and C. Kunz$^*$ and
                      M. Haenel and I. W. Blau and M. Munder and A. Jauch and B.
                      Schurich and T. Hielscher$^*$ and M. Merz and B.
                      Huegle-Doerr and A. Seckinger and D. Hose and J. Hillengass
                      and M. S. Raab and K. Neben and H.-W. Lindemann and M. Zeis
                      and C. Gerecke and I. G. H. Schmidt-Wolf and K. Weisel and
                      C. Scheid and H. Salwender and H. Goldschmidt},
      title        = {{P}hase {III} trial of bortezomib, cyclophosphamide and
                      dexamethasone ({VCD}) versus bortezomib, doxorubicin and
                      dexamethasone ({PA}d) in newly diagnosed myeloma.},
      journal      = {Leukemia},
      volume       = {29},
      number       = {8},
      issn         = {1476-5551},
      address      = {Basingstoke},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2017-03074},
      pages        = {1721 - 1729},
      year         = {2015},
      abstract     = {We aimed at demonstrating non-inferiority of
                      bortezomib/cyclophosphamide/dexamethasone (VCD) compared to
                      bortezomib/doxorubicin/dexamethasone (PAd) induction therapy
                      with respect to very good partial response rates or better
                      (⩾VGPR) in 504 newly diagnosed, transplant-eligible
                      multiple myeloma patients. VCD was found to be non-inferior
                      to PAd with respect to ⩾VGPR rates (37.0 versus $34.3\%,$
                      P=0.001). The rates of progressive disease (PD) were $0.4\%$
                      (VCD) versus $4.8\%$ (PAd; P=0.003). In the PAd arm, 11 of
                      12 patients with PD had either renal impairment (creatinine
                      ⩾2 mg/dl) at diagnosis or the cytogenetic abnormality
                      gain 1q21, whereas no PD was observed in these subgroups in
                      the VCD arm. Leukocytopenia/neutropenia (⩾3°) occurred
                      more frequently in the VCD arm $(35.2\%$ versus $11.3\%,$
                      P<0.001). Neuropathy rates (⩾2°) were higher in the PAd
                      group (14.9 versus $8.4\%,$ P=0.03). Serious adverse events,
                      both overall and those related to thromboembolic events,
                      were higher in the PAd group (32.7 versus $24.0\%,$ P=0.04
                      and 2.8 versus $0.4\%,$ P=0.04). Stem cell collection was
                      not impeded by VCD. VCD is as effective as PAd in terms of
                      achieving ⩾VGPR rates with fewer PD and has a favorable
                      toxicity profile. Therefore, VCD is preferable to PAd as
                      induction therapy.},
      keywords     = {Boronic Acids (NLM Chemicals) / Pyrazines (NLM Chemicals) /
                      Bortezomib (NLM Chemicals) / Dexamethasone (NLM Chemicals) /
                      Doxorubicin (NLM Chemicals) / Cyclophosphamide (NLM
                      Chemicals)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25787915},
      doi          = {10.1038/leu.2015.80},
      url          = {https://inrepo02.dkfz.de/record/127048},
}